Moderna and Merck's personalised mRNA vaccine shows promising Phase 3 results in melanoma treatment, potentially revolutionising cancer care with tailored immunotherapy.

Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.

In light of recent wins for mRNA vaccine makers, UCSC RNA Center Co-Director Jeremy Sanford describes the versatility of the mRNA platform and how it quickens vaccine production

Even with a modest 25% success rate for the company's current phase 2 programs, Moderna should be able to launch enough new products over the next five years to improve its financial results. So, the stock remains a buy, at least for investors willing to hold onto Moderna's shares for at least five years.

A personalized vaccine developed by Moderna Inc. and Merck & Co. helped reduce the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology.

Moderna MRNA stock fell 20%% to $138, compared with Wednesday’s close of $174.38. The decline followed a more than doubling of the shares on August 19 after Moderna and Merck announced positive results from the Phase 3 INTerpath-001 study of their personalized mRNA cancer vaccine, intismeran autogene.

Moderna stock surged on Phase 3 mRNA cancer vaccine results with Merck, breaking key moving averages and hitting record RSI.

Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest.